


Erectile Dysfunction Market Size to Reach US\$ 3.9 Billion by 2034 | CAGR of 6.53%

BROOKLYN, NY, USA, April 9, 2024
/EINPresswire.com/ -- How much is
erectile dysfunction industry worth?

The erectile dysfunction market reached a value of US\$ 1.9 Billion in 2023 and expects to reach US\$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 6.53% during 2024-2034.

The [erectile dysfunction market report](#) offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the

market share of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the erectile dysfunction market.



Request for a Free Sample of this Report: <https://www.imarcgroup.com/erectile-dysfunction-market/requestsampl>

Erectile Dysfunction Market Trends:

Erectile dysfunction (ED), also known as impotence, refers to the incapability to maintain or achieve an erection strong enough for sexual activity. The erectile dysfunction market is significantly growing due to an increasing prevalence of various conditions, such as diabetes, hypertension, and obesity, that are major contributors to the underlying ailment. For instance,

according to the article published by the NIH, sexual dysfunctions are common in people with diabetes and may arise from a variety of vascular, neurologic, and hormonal derangements. Numerous advancements in medical research have led to the development of numerous regimens, including oral treatments, injectable drugs, and devices, expanding the therapeutic options for patients.

For instance, Lupin Limited launched Sildenafil for oral suspension, 10 mg/mL, having received approval from the US FDA. Another factor driving the market growth is the increasing acceptance and decreasing stigma linked to seeking treatment for sexual health problems. Additionally, since the prevalence of erectile dysfunction rises with age, the elderly population is a crucial target market for ED therapies. Also, the number of patients in need of treatment is increasing due to this demographic trend. The escalating online pharmacies and telehealth services are making it easier for patients to access ED medications. The industry has expanded due to the release of generic versions of well-known medications, which have reduced costs and increased accessibility. In addition to this, pharmaceutical companies are consistently spending in R&D to invent and improve ED drugs, thereby indicating substantial market growth in the coming years.

Countries Covered:

- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan

Analysis Covered Across Each Country:

- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the erectile dysfunction market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the erectile dysfunction market
- Reimbursement scenario in the market
- In-market and pipeline drugs

This report also provides a detailed analysis of the current erectile dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

- Drug Overview

- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the erectile dysfunction market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these Key Players:

VIVUS

Pfizer

Eli Lilly and Company

Bayer

Ask Analyst for Customization and Explore Full Report With TOC & List of Figures:

<https://www.imarcgroup.com/request?type=report&id=6858&flag=C>

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/702249771>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.